


thereof a composition comprising a compound having the structure



wherein

R<sub>1</sub> is benzyl, halobenzyl, methoxybenzyl-, cyanobenzyl, or naphthalenylmethyl;

R<sub>2</sub> is ethyl or propyl;

R<sub>2'</sub> is hydrogen;


R<sub>5</sub> is hydrogen;

R<sub>6</sub> is hydrogen;

R<sub>7</sub> is halo, cyano, methoxy or hydrogen;


R<sub>8</sub> is hydrogen; and

R<sub>12</sub> is optionally substituted imidazolyl having the structure



wherein R<sub>10</sub>, R<sub>10'</sub>, R<sub>14</sub> and R<sub>14'</sub> are independently hydrogen or optionally substituted C<sub>1</sub>C<sub>4</sub> alkyl; and R<sub>9</sub> is optionally substituted phenyl.

**113.** A method for the treatment of a cellular proliferative disease comprising administering to a subject in need thereof a composition comprising a compound having the structure



wherein

R<sub>1</sub> is benzyl, halobenzyl, methoxybenzyl-, cyanobenzyl, or naphthalenylmethyl;

R<sub>2</sub> is ethyl or propyl;

R<sub>2'</sub> is hydrogen;


R<sub>5</sub> is hydrogen;

R<sub>6</sub> is hydrogen;

R<sub>7</sub> is halo, cyano, methoxy or hydrogen;

R<sub>8</sub> is hydrogen; and

R<sub>12</sub> is optionally substituted imidazole, having the structure



wherein R<sub>13</sub> is hydrogen and R<sub>13'</sub> is hydrogen or optionally substituted alkyl; and R<sub>9</sub> is optionally substituted aryl.

**114.** A method according to claim 68 wherein R<sub>2</sub> and R<sub>2'</sub> are each attached to a stereogenic center having an R-configuration, or a pharmaceutically acceptable salt or solvate thereof.

**115.** A method according to claim 68 wherein the compound of Formula I is a hydrochloric, phosphoric, or oxalic acid salt.

**116.** A method according to claim 68, wherein said composition further comprises a chemotherapeutic agent other than a compound of Formula I or a pharmaceutical salt or solvate thereof.

**117.** A method according to claim 116, wherein said composition further comprises a taxane.

**118.** A method according to claim 116, wherein said composition further comprises a vinca alkaloid.

**119.** A method according to claim 116, wherein said composition further comprises a topoisomerase I inhibitor.

\* \* \* \* \*